Skip to main content

Aclaris Therapeutics Value Stock - Dividend - Research Selection

Aclaris therapeutics

ISIN: US00461U1051 , WKN: A1412H

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. It operates in two segments, Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company's products under development include ATI-450 an investigational oral, novel, small molecule selective MK2 inhibitor compound for the treatment of rheumatoid arthritis; ATI-1777 soft inhibitor for atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3, or ITJ, inhibitor compound, for the treatment of psoriasis inflammatory bowel disease. Further, it provides contract research services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Stocks To Watch: Nvidia, Lowe's, Deere And Best Buy Line Up To Report

2023-11-18
Stay informed of key market events with Seeking Alpha's Stocks to Watch newsletter. Get previews of upcoming IPOs, earnings reports, and more.

Largest borrow rate increases among liquid names

2023-11-17
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Catalyst watch: Nvidia earnings, Broadcom-VMware drama, auto show buzz and holiday sales blitz

2023-11-17
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Down -84.82% in 4 Weeks, Here's Why You Should You Buy the Dip in Aclaris (ACRS)

2023-11-16
Aclaris (ACRS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Biotech Alert: Searches spiking for these stocks today

2023-11-16
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Cantor Fitzgerald Downgrades Aclaris Therapeutics (ACRS)

2023-11-14

Aclaris (ACRS) Lead Drug Fails Rheumatoid Arthritis Study

2023-11-14
Aclaris (ACRS) decides to stop the development of its lead drug after top-line data from a mid-stage study did not achieve any study goals. Shares plunge 86% following the news.

12 Health Care Stocks Moving In Tuesday's Intraday Session

2023-11-14
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Aclaris Therapeutics price target lowered to $3 from $22 at Evercore ISI

2023-11-14
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

The Latest Analyst Ratings for Aclaris Therapeutics

2023-11-14
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.